Histafen (Chlorpheniramine maleate): Discontinuation

Douglas Pharmaceuticals are discontinuing Histafen.

Reason for this discontinuation

The formulation for Histafen has remained unchanged for 50 years. Douglas only supplies Histafen to New Zealand. Due to the relatively low use and high cost of manufacturing compliance, Douglas have advised it is no longer sustainable to continue manufacturing and supply.

When will this happen

Current stocks of Histafen were expected to run out in July 2023. 

We will delist this product from the Schedule in early 2024.

Alternative products

There are ample modern antihistamines on the market.

Schedule listings for all antihistamines(external link)

Who to contact

If you use Histafen, talk to the person who prescribed it to you about  the best alternative antihistamine for you. Pharmac cannot comment on any individual's clinical circumstances, so we cannot advise you.

If you have questions relating to funding for Histafen, email enquiry@pharmac.govt.nz